Diabetic Neuropathy

• Hyperglycemia-driven metabolic dysfunction: Sustained elevation of intracellular glucose in neurons (which lack insulin-dependent glucose transporters) leads to activation of the polyol pathway, accumulation of sorbitol and fructose, generation of advanced glycation end products (AGEs), increased protein kinase C (PKC) signaling, and increased oxidative stress through excessive NADPH depletion. Mitochondrial dysfunction ensues with impaired ATP production.

• Microvascular ischemia: Chronic hyperglycemia causes endothelial dysfunction, reduced vascular endothelial growth factor (VEGF) expression, increased vascular permeability, and narrowing of endoneurial blood vessels, leading to hypoxia and inadequate oxygen/nutrient delivery to nerve fibers. Nitric oxide (NO) bioavailability is reduced, worsening vasodilation impairment.

• Inflammatory and immune-mediated injury: Persistent hyperglycemia triggers low-grade chronic inflammation with activation of toll-like receptors (TLRs), increased TNF-α and IL-6 production, activation of the NLRP3 inflammasome, complement system activation, and recruitment of macrophages into nerve tissue. Microglial activation in dorsal root ganglia contributes to small fiber neuropathy development.

• Neuronal degeneration and impaired regeneration: Axonal degeneration occurs through calcium overload (via TRPV1 and other calcium channels), mitochondrial dysfunction, reduced neurotrophic support (decreased NGF and GDNF signaling), impaired mitochondrial dynamics (fusion/fission), and activation of calpains and caspases. Myelin loss and demyelination occur secondary to Schwann cell dysfunction.

Major causes and risk factors

• Hyperglycemia severity and duration: Poor glycemic control (elevated HbA1c) is the dominant modifiable risk factor; cumulative hyperglycemia exposure (measured by HbA1c trajectory) predicts neuropathy development more than current glucose level alone.

• Type of diabetes: Both type 1 and type 2 diabetes carry risk; type 1 diabetes with longer duration (>10 years) shows higher prevalence; type 2 diabetes with poor control shows accelerated progression.

• Metabolic comorbidities: Hypertension (independent risk factor through microvascular injury), dyslipidemia (particularly elevated triglycerides), obesity, and metabolic syndrome amplify neuropathic risk. Insulin resistance itself may contribute independent of glucose.

• Genetic predisposition: Polymorphisms in sorbitol dehydrogenase, aldose reductase, TRPV1, and genes affecting inflammatory responses influence individual susceptibility. First-degree relatives of patients with severe neuropathy have higher risk.

• Secondary metabolic factors: Vitamin B12 deficiency (particularly in metformin users), low magnesium, elevated homocysteine, and chronic kidney disease accelerate neuropathy progression.

• Duration of diabetes: Neuropathy prevalence increases with disease duration; approximately 50% of patients with 25+ years of diabetes develop clinically evident neuropathy.

• Age at diabetes onset: Earlier age at onset predicts longer disease duration and higher cumulative metabolic insult.

Cardinal symptoms

• Distal sensory symptoms (classic pattern): Typically begins in feet in a "stocking-glove" distribution; patients report numbness, tingling, paresthesias (pins-and-needles), or burning pain that ascends proximally. Symptoms often worse at night and can significantly impair sleep quality.

• Neuropathic pain: Described as burning, lancinating, electric-shock-like, or "walking on needles"; pain may paradoxically develop as small nerve fibers regenerate after initial loss (paradoxical pain).

• Large fiber dysfunction symptoms: Proprioceptive loss leads to gait imbalance and falls; weakness (especially foot extensors), difficulty with fine motor tasks, and sensory ataxia occur.

• Small fiber dysfunction symptoms: Restless legs syndrome, allodynia (pain with light touch), temperature sensation loss, autonomic instability (postural dizziness), and impaired pain/temperature sensation.

Physical examination findings

• Diminished or absent reflexes: Achilles reflex loss (earliest finding) followed by patellar reflex loss; indicates large fiber damage.

• Stocking-glove sensory loss: Decreased vibration sense (256 Hz tuning fork), position sense, and temperature sensation in lower extremities; glove distribution in hands in advanced disease. Monofilament testing (10-gram monofilament) reveals pressure sensation loss.

• Distal motor weakness: Foot drop from tibialis anterior weakness; intrinsic foot muscle atrophy; ankle dorsiflexion weakness (foot slap gait).

• Trophic changes: Smooth, shiny skin; hair loss on feet/lower legs; skin atrophy; nail dystrophy; callus formation over pressure points; dry, cracked heels.

• Charcot arthropathy: Painless joint destruction with swelling, deformity, and instability (particularly ankle/midfoot); occurs from repeated trauma to insensate joints.

• Ulceration: Painless foot ulcers on pressure-bearing areas (plantar surface, heel, ball of foot); often infected by time patient seeks care.

Autonomic manifestations

• Cardiovascular: Orthostatic hypotension (postural dizziness, syncope), resting tachycardia, fixed heart rate (loss of heart rate variability), silent myocardial ischemia.

• Gastrointestinal: Gastroparesis (nausea, vomiting, early satiety, unpredictable blood glucose), constipation, fecal incontinence.

• Genitourinary: Erectile dysfunction (early manifestation), impaired bladder emptying with urinary retention, decreased sensation of full bladder.

• Sudomotor: Distal anhidrosis (loss of sweating) with compensatory hyperhidrosis on upper body/trunk; impaired thermoregulation.

Diagnostic approach combines clinical assessment with objective testing

• Clinical diagnosis: Based on symptoms (distal paresthesias, pain, numbness) and consistent examination findings (diminished reflexes, stocking-glove sensory loss) in a patient with documented diabetes. Should exclude alternative causes with history, medication review (stavudine, didanosine, vincristine, chemotherapy agents), and assessment for alcohol use.

• Quantitative sensory testing (QST): Objective measurement of vibratory and thermal thresholds using standardized instruments; demonstrates small and large fiber dysfunction. Abnormal thresholds in distal lower extremities with proximal sparing confirms length-dependent pattern. Less subjective than monofilament testing but requires patient cooperation and multiple testing sites.

• Intraepidermal nerve fiber (IENF) density via skin biopsy: Gold standard for small fiber neuropathy; 3mm punch biopsy from lateral distal leg shows reduced IENF density compared to age-adjusted controls. Density <5 fibers/mm correlates with symptomatic small fiber neuropathy. More sensitive than electrophysiology for early small fiber involvement.

• Electromyography (EMG) and nerve conduction studies (NCS): Demonstrates large fiber involvement; findings include:
• Reduced amplitude of sensory nerve action potentials (SNAPs) in sural, superficial peroneal nerves
• Prolonged distal latencies and reduced conduction velocities (demyelination pattern less common than axonal)
• Sural nerve most sensitive; peroneal nerve next
• Reduced compound muscle action potential (CMAP) amplitudes in motor nerves
• EMG may show motor unit action potential abnormalities and increased insertional activity in affected muscles
• Normal in pure small fiber neuropathy; sensitivity ~80% for moderate-to-severe DSPN

• Autonomic testing: Cardiovascular reflex tests (deep breathing, Valsalva maneuver, orthostatic vital signs), quantitative sudomotor axon reflex test (QSART), heart rate variability analysis, and skin sympathetic response assess autonomic involvement. Abnormal response to Valsalva (blunted heart rate increase) indicates vagal dysfunction.

• Laboratory studies:
• HbA1c: Elevated (typically >8%) at diagnosis; correlation with neuropathy severity validates glycemic control importance
• Fasting glucose: Elevated (>126 mg/dL confirms diabetes if not previously known)
• Vitamin B12 and folate: Screen for deficiency, particularly if on metformin; methylmalonic acid/homocysteine elevation suggests B12 deficiency
• TSH: Hypothyroidism can mimic/worsen neuropathy
• Serum protein electrophoresis: Consider if atypical presentation to exclude monoclonal gammopathy-related neuropathy
• Urinalysis and urine microalbumin: Assesses diabetic kidney disease (often coexists)

• Imaging findings: MRI of brain/spinal cord unnecessary for routine DSPN diagnosis but may be considered if atypical presentation, acute-onset symptoms, or focal deficits suggest alternative diagnosis (demyelinating disease, structural lesions). Foot imaging (plain films, MRI) helpful in evaluating suspected Charcot arthropathy or complex foot infections.

• Diagnostic criteria: No single universally accepted diagnostic criteria; diagnosis typically requires:

1. 1.Documented diabetes (type 1 or 2)
2. 2.Symptoms consistent with neuropathy (distal paresthesias, pain, numbness)
3. 3.Physical examination abnormalities (diminished reflexes, sensory loss in distal extremities)
4. 4.Exclusion of other causes (alternative medications, B12 deficiency, hypothyroidism, other systemic diseases)
5. 5.Objective evidence preferred (NCS/EMG abnormalities or abnormal QST/IENF density), though clinical diagnosis accepted when objective testing unavailable

Comprehensive management approach

• Primary intervention—Glycemic control: Intensive glycemic control with insulin, metformin, or other agents targeting HbA1c <7% (individualized targets for older adults or those with comorbidities) is the most effective strategy to prevent neuropathy onset and slow progression. DCCT and UKPDS trials established glucose as modifiable risk factor; every 1% reduction in HbA1c correlates with reduced neuropathy progression. Early intervention within 5 years of diabetes diagnosis yields maximal benefit.

• First-line pharmacological treatment for neuropathic pain:
• Gabapentin (300-3600 mg daily divided dosing): GABA analog that reduces calcium influx and neurotransmitter release; initiate 300 mg daily, titrate to 900-1800 mg daily in divided doses. Effective for both burning pain and paresthesias. Side effects: dizziness, somnolence, weight gain; requires renal dose adjustment.
• Pregabalin (150-600 mg daily): Structural analog of gabapentin with greater bioavailability and more predictable pharmacokinetics; initiate 75 mg daily, titrate to 150-300 mg daily in divided doses. Similar efficacy to gabapentin with fewer dosing requirements. FDA-approved for diabetic neuropathy. Side effects: same as gabapentin.

• Second-line pharmacological treatment:
• Duloxetine (60 mg daily): Serotonin-norepinephrine reuptake inhibitor (SNRI) with proven efficacy in diabetic neuropathic pain; take as single daily dose. Particularly effective for burning pain. Monitor for hyponatremia (SIADH), especially in elderly; contraindicated with narrow-angle glaucoma or uncontrolled hypertension. Can be combined with gabapentin/pregabalin for enhanced pain control.
• Venlafaxine (150-225 mg daily): Extended-release SNRI alternative with evidence supporting neuropathic pain relief; similar mechanism to duloxetine.
• Topical capsaicin: Depletes substance P from C-fibers; useful for localized pain areas. Apply 0.075% cream three to four times daily; causes transient burning before analgesia. Avoid near eyes/mucous membranes.
• Topical lidocaine patches (5%): Non-systemic local anesthetic; apply to areas of maximal pain for maximum 12 hours daily. Useful for localized neuropathic pain without systemic side effects.

• Adjunctive/third-line options:
• Tramadol (50-400 mg daily): Weak mu-opioid with norepinephrine/serotonin reuptake inhibition; reserve for inadequate response to first/second-line agents due to abuse potential and seizure risk. Avoid in patients with seizure disorder or those taking SSRIs/SNRIs (serotonin syndrome risk).
• Alpha-lipoic acid (600 mg daily IV or oral): Antioxidant with theoretical anti-inflammatory benefits; modest evidence for symptomatic improvement; preferred in European guidelines. Generally well-tolerated.
• Tricyclic antidepressants (amitriptyline 50-150 mg nightly, nortriptyline 50-150 mg nightly): Effective for neuropathic pain via norepinephrine/serotonin reuptake inhibition; avoid in elderly due to anticholinergic effects, orthostatic hypotension, and cardiac conduction delays.

• Non-pharmacological interventions:
• Foot care education and prevention: Daily foot inspection for ulcers/cracks, proper footwear (cushioned, non-restrictive), nail care, skin hygiene, podiatry referral for high-risk feet. Prevents catastrophic ulceration/amputation.
• Physical therapy: Gait training, balance/proprioceptive exercises, strength training to improve stability and reduce fall risk. Particularly important in those with ataxia or proximal weakness.
• Structured exercise program: Regular aerobic and resistance exercise improves glycemic control, reduces pain perception, and strengthens lower extremities. Target 150 minutes/week moderate activity.
• Transcutaneous electrical nerve stimulation (TENS): May provide symptomatic relief for some patients; evidence limited but low-risk option.
• Psychological support: Cognitive-behavioral therapy and pain coping strategies help manage chronic neuropathic pain and associated depression/anxiety.

• Treatment of autonomic manifestations:
• Orthostatic hypotension: Compression stockings, increased salt/fluid intake, midodrine (5-10 mg three times daily), or fludrocortisone (0.1-0.2 mg daily); educate on gradual position changes and supine leg elevation.
• Gastroparesis: Small frequent meals, prokinetic agents (metoclopramide 10 mg three times daily, domperidone), dietary modifications (low fat, low fiber); consider gastric pacing in severe refractory cases.
• Erectile dysfunction: Phosphodiesterase-5 inhibitors (sildenafil, tadalafil); consider testosterone replacement if hypogonadism present.
• Urinary retention: Intermittent catheterization, bethanechol (parasympathomimetic), alpha-blocker therapy; monitor post-void residual.

• Monitoring parameters:
• Glycemic control: Check HbA1c every 3 months during therapy intensification, then every 6 months once stable; home glucose monitoring as per diabetes regimen.
• Medication efficacy: Reassess pain control at 2-4 weeks after initiation; document impact on function, sleep, quality of life.
• Adverse effects: Monitor for CNS effects (gabapentin/pregabalin), hyponatremia (duloxetine), gastrointestinal upset (alpha-lipoic acid); assess orthostatic vital signs on antidepressants.
• Complication surveillance: Foot examination at each

Complications of the disease

• Neuropathic foot ulceration: Loss of protective sensation removes the pain feedback that normally prompts offloading, so repetitive pressure over metatarsal heads and heel produces callus, then a painless punched-out plantar ulcer. The ADA Standards of Care make annual comprehensive foot exam plus more frequent inspection in insensate feet the core preventive measure.
• Diabetic foot infection and osteomyelitis: Ulcer becomes a portal for polymicrobial invasion; a positive probe-to-bone test or an ulcer that fails to heal signals underlying osteomyelitis. Deep abscess, crepitus, rapidly spreading erythema, or systemic toxicity indicates a limb-threatening or necrotizing infection — a surgical emergency requiring urgent debridement plus broad-spectrum antibiotics per IDSA/IWGDF diabetes-related foot infection guidance.
• Charcot neuroarthropathy: Autonomic denervation causes hyperemic bone resorption while insensate joints keep bearing load, giving a hot, swollen, erythematous but relatively painless foot with intact pulses. Urgent — immediate total-contact casting/offloading prevents rocker-bottom collapse; the classic distractor is treating it as cellulitis.
• Cardiovascular autonomic neuropathy: Vagal then sympathetic denervation produces resting tachycardia, fixed heart rate, and orthostatic hypotension; it underlies silent myocardial ischemia (infarction presenting as dyspnea, nausea, or hyperglycemia rather than chest pain) and perioperative hemodynamic instability. An emergency when it masks ACS.
• Hypoglycemia unawareness: Loss of adrenergic counterregulatory warning symptoms; ADA advises relaxing glycemic targets when this appears.
• Falls, fractures, and gastroparesis: Proprioceptive loss causes sensory ataxia; delayed gastric emptying causes erratic postprandial glucose and bezoar formation.

Complications of treatment

• Gabapentinoids: Sedation, dizziness, peripheral edema, and falls; accumulation in CKD requires renal dose reduction. FDA warns of serious respiratory depression when combined with opioids or in severe pulmonary disease.
• Duloxetine/venlafaxine: Hyponatremia (SIADH), hypertension, hepatotoxicity, and serotonin syndrome — especially with tramadol.
• TCAs: Anticholinergic delirium and urinary retention, orthostasis, and QRS/QT prolongation in overdose.
• Metoclopramide: Tardive dyskinesia (boxed warning) limits use to short courses.
• Treatment-induced neuropathy of diabetes (insulin neuritis): Acute painful small-fiber neuropathy and autonomic dysfunction after rapid HbA1c lowering.
• Midodrine: Supine hypertension; metformin: B12 deficiency worsening neuropathy.

• Length-dependent "dying-back" pattern is the signature: the longest axons fail first, so symptoms begin in the toes and only reach the hands once leg symptoms approach the knees — the stocking-glove distribution. Loss of the ankle (Achilles) reflex and vibration sense at the great toe are the earliest objective findings.
• Single best next step in a diabetic with numb feet: bedside 10-g monofilament testing plus one other modality (vibration with a 128 Hz tuning fork, pinprick, temperature, or ankle reflex). ADA recommends screening all type 2 patients at diagnosis and type 1 patients five years after diagnosis, then annually. Electrodiagnostic testing is not required for typical distal symmetric polyneuropathy.
• Always check B12 before blaming diabetes, particularly in long-term metformin users — the ADA specifically flags this, and B12 deficiency produces a clinically similar but dorsal-column-predominant picture with hyperreflexia rather than areflexia.
• The association examiners love: an insensate foot with a hot, swollen, deformed midfoot and bounding pedal pulses is Charcot neuroarthropathy, not cellulitis — the tip-off is minimal pain and erythema that fades with limb elevation. Answer: immobilization and offloading.
• Pupil-sparing CN III palsy in a diabetic reflects ischemic infarction of central fibers with sparing of superficial parasympathetics; pupil involvement points instead to a posterior communicating artery aneurysm — that distinction is the recurring distractor.
• Diabetic amyotrophy (lumbosacral radiculoplexus neuropathy): asymmetric proximal thigh pain, quadriceps wasting, and weight loss, often in older type 2 patients; it is immune/microvasculitic and usually improves spontaneously.
• Pharmacology pearl: the AAN guideline on painful diabetic polyneuropathy endorses gabapentinoids, SNRIs, TCAs, and sodium-channel blockers as reasonable initial options and recommends against opioids for chronic use — picking oxycodone is the trap answer.
• Glycemic control prevents but does not reverse: intensive control markedly reduces incident neuropathy in type 1 diabetes (DCCT), with more modest effect in type 2 — so tight control is not the answer to "how do I relieve this patient's burning pain tonight."